[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Zheng, R., Zhang, S., Zeng, H., et al. (2022) Cancer Incidence and Mortal-ity in China, 2016. Journal of the National Cancer Center, 2, 1-9. https://doi.org/10.1016/j.jncc.2022.02.002
|
[3]
|
Qiu, H., Cao, S. and Xu, R. (2021) Cancer Incidence, Mortality, and Burden in China: A Time-Trend Analysis and Comparison with the United States and United Kingdom Based on the Global Epidemiological Data Released in 2020. Cancer Communications, 41, 1037-1048. https://doi.org/10.1002/cac2.12197
|
[4]
|
宋文鹏, 王彦, 谢嘉渝, 等. 中国人饮食因素与食管癌的相关性[J]. 临床与病理杂志, 2021, 41(8): 1915-1924.
|
[5]
|
Cogliano, V.J., Baan, R., Straif, K., et al. (2011) Preventable Expo-sures Associated with Human Cancers. Journal of the National Cancer Institute, 103, 1827-1839. https://doi.org/10.1093/jnci/djr483
|
[6]
|
Rumgay, H., Arnold, M., Laversanne, M., et al. (2021) International Trends in Esophageal Squamous Cell Carcinoma and Adenocarcinoma Incidence. The American Journal of Gastroenter-ology, 116, 1072-1076.
https://doi.org/10.14309/ajg.0000000000001121
|
[7]
|
Liang, H., Fan, J.-H. and Qiao, Y.-L. (2017) Epidemiology, Etiology, and Prevention of Esophageal Squamous Cell Carcinoma in China. Cancer Biology & Medicine, 14, 33-41. https://doi.org/10.20892/j.issn.2095-3941.2016.0093
|
[8]
|
Napier, K.J., Scheerer, M. and Misra, S. (2014) Esoph-ageal Cancer: A Review of Epidemiology, Pathogenesis, Staging Workup and Treatment Modalities. World Journal of Gastrointestinal Oncology, 6, 112-120.
https://doi.org/10.4251/wjgo.v6.i5.112
|
[9]
|
Bleiberg, H., Conroy, T., Paillot, B., et al. (1997) Randomised Phase II Study of Cisplatin and 5-Fluorouracil (5-FU) Versus Cisplatin Alone in Advanced Squamous Cell Oesophageal Cancer. European Journal of Cancer, 33, 1216-1220.
https://doi.org/10.1016/S0959-8049(97)00088-9
|
[10]
|
Lee, S.J., Kim, S., Kim, M., et al. (2015) Capecitabine in Combination with Either Cisplatin or Weekly Paclitaxel as a First-Line Treatment for Metastatic Esophageal Squamous Cell Carcinoma: A Randomized Phase II Study. BMC Cancer, 15, Article No. 693. https://doi.org/10.1186/s12885-015-1716-9
|
[11]
|
Moehler, M., Maderer, A., Thuss-Patience, P.C., et al. (2020) Cisplatin and 5-Fluorouracil with or without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients with Non-Resectable, Advanced or Metastatic Oesophageal Squamous Cell Cancer: A Prospective, Open-Label, Ran-domised Phase III AIO/EORTC Trial (POWER). Annals of Oncology, 31, 228-235. https://doi.org/10.1016/j.annonc.2019.10.018
|
[12]
|
Luo, H., Lu, J., Bai, Y., et al. (2021) Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA, 326, 916-925. https://doi.org/10.1001/jama.2021.12836
|
[13]
|
Sun, J.-M., Shen, L., Shah, M.A., et al. (2021) Pembrolizumab plus Chemotherapy Versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study. Lancet, 398, 759-771. https://doi.org/10.1016/S0140-6736(21)01234-4
|
[14]
|
Ishida, Y., Agata, Y., Shibahara, K. and Honjo, T. (1992) Induced Expression of PD-1, a Novel Member of the Immunoglobulin Gene Superfamily, Upon Programmed Cell Death. The EMBO Journal, 11, 3887-3895.
https://doi.org/10.1002/j.1460-2075.1992.tb05481.x
|
[15]
|
Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., et al. (2009) Tumor Antigen-Specific CD8 T Cells Infiltrating the Tumor Express High Levels of PD-1 and Are Functionally Impaired. Blood, 114, 1537-1544.
https://doi.org/10.1182/blood-2008-12-195792
|
[16]
|
Salmaninejad, A., Khoramshahi, V., Azani, A., et al. (2018) PD-1 and Cancer: Molecular Mechanisms and Polymorphisms. Immunogenetics, 70, 73-86. https://doi.org/10.1007/s00251-017-1015-5
|
[17]
|
Sanmamed, M.F. and Chen, L. (2014) Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation. The Cancer Journal, 20, 256-261. https://doi.org/10.1097/PPO.0000000000000061
|
[18]
|
Sharpe, A.H., Wherry, E.J., Ahmed, R. and Freeman, G.J. (2007) The Function of Programmed Cell Death 1 and Its Ligands in Regulating Autoimmunity and Infection. Nature Immunology, 8, 239-245. https://doi.org/10.1038/ni1443
|
[19]
|
Ohaegbulam, K.C., Assal, A., Lazar-Molnar, E., Yao, Y. and Zang, X. (2015) Human Cancer Immunotherapy with Antibodies to the PD-1 and PD-L1 Pathway. Trends in Molecular Medicine, 21, 24-33.
https://doi.org/10.1016/j.molmed.2014.10.009
|
[20]
|
Dong, P., Xiong, Y., Yue, J., Hanley, S.J.B. and Watari, H. (2018) Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion. Frontiers in Oncology, 8, Article No. 386.
https://doi.org/10.3389/fonc.2018.00386
|
[21]
|
Nunes-Xavier, C.E., Angulo, J.C., Pulido, R. and López, J.I. (2019) A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma. Current Urology Reports, 20, Article No. 1.
https://doi.org/10.1007/s11934-019-0866-8
|
[22]
|
Sharpe, A.H. and Freeman, G.J. (2002) The B7-CD28 Superfam-ily. Nature Reviews Immunology, 2, 116-126.
https://doi.org/10.1038/nri727
|
[23]
|
Francisco, L.M., Sage, P.T. and Sharpe, A.H. (2010) The PD-1 Pathway in Tolerance and Autoimmunity. Immunological Reviews, 236, 219-242. https://doi.org/10.1111/j.1600-065X.2010.00923.x
|
[24]
|
Pardoll, D.M. (2012) The Blockade of Immune Check-points in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[25]
|
Brunet, J.-F., Denizot, F., Luciani, M.-F., et al. (1987) A New Member of the Immunoglobulin Superfamily—CTLA-4. Nature, 328, 267-270. https://doi.org/10.1038/328267a0
|
[26]
|
Lenschow, D.J., Zeng, Y., Thistlethwaite, J.R., et al. (1992) Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg. Science, 257, 789-792. https://doi.org/10.1126/science.1323143
|
[27]
|
Linsley, P.S., Wallace, P.M., Johnson, J., et al. (1992) Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule. Science, 257, 792-795. https://doi.org/10.1126/science.1496399
|
[28]
|
Chen, D.S. and Mellman, I. (2017) Elements of Cancer Immunity and the Cancer-Immune Set Point. Nature, 541, 321-330. https://doi.org/10.1038/nature21349
|
[29]
|
Qureshi, O.S., Zheng, Y., Nakamura, K., et al. (2011) Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4. Science, 332, 600-603. https://doi.org/10.1126/science.1202947
|
[30]
|
Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J. and Al-lison, J.P. (2009) Blockade of CTLA-4 on Both Effector and Regulatory T Cell Compartments Contributes to the Anti-tumor Activity of Anti-CTLA-4 Antibodies. Journal of Experimental Medicine, 206, 1717-1725. https://doi.org/10.1084/jem.20082492
|
[31]
|
Ribas, A. (2012) Tumor Immunotherapy Directed at PD-1. New Eng-land Journal of Medicine, 366, 2517-2519.
https://doi.org/10.1056/NEJMe1205943
|
[32]
|
Janjigian, Y.Y., Shitara, K., Moehler, M., et al. (2021) First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. Lancet, 398, 27-40. https://doi.org/10.1016/S0140-6736(21)00797-2
|
[33]
|
Lu, Z., Wang, J., Shu, Y., et al. (2022) Sintilimab versus Placebo in Combination with Chemotherapy as First Line Treatment for Locally Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ORIENT-15): Multicentre, Randomised, Double Blind, Phase 3 Trial. BMJ, 377, e068714. https://doi.org/10.1136/bmj-2021-068714
|
[34]
|
Wang, Z.-X., Cui, C., Yao, J., et al. (2022) Toripalimab plus Chem-otherapy in Treatment-Naïve, Advanced Esophageal Squamous Cell Carcinoma (JUPITER-06): A Multi-Center Phase 3 Trial. Cancer Cell, 40, 277-288.
https://doi.org/10.1016/j.ccell.2022.02.007
|
[35]
|
Kelly, R.J., Ajani, J.A., Kuzdzal, J., et al. (2021) Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. New England Journal of Medicine, 384, 1191-1203. https://doi.org/10.1056/NEJMoa2032125
|
[36]
|
Lordick, F., Mariette, C., Haustermans, K., et al. (2016) Oesophageal Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology, 27, v50-v57. https://doi.org/10.1093/annonc/mdw329
|
[37]
|
National Comprehensive Cancer Network (NCCN) (2020) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Esophageal and Esophagogastric Junction Cancers. Version 4.
|
[38]
|
National Comprehensive Cancer Network (NCCN) (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Gastric Cancer. Version 2.
|
[39]
|
Saeed, A., Park, R., Dai, J., et al. (2023) Cabozan-tinib plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies: Phase Ib CAMILLA Trial Results. Cell Reports Medicine, 4, Article ID: 100916.
https://doi.org/10.1016/j.xcrm.2023.100916
|
[40]
|
Cowzer, D., Wu, A.J.-C., Sihag, S., et al. (2023) Durvalumab and Pet-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma—A Phase Ib/II Study. Annals of Sur-gery.
https://doi.org/10.1097/SLA.0000000000005818
|
[41]
|
Janjigian, Y.Y., Bendell, J., Calvo, E., et al. (2018) Check-Mate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab plus Ipilimumab in Patients with Metastatic Esoph-agogastric Cancer. Journal of Clinical Oncology, 36, 2836-2844. https://doi.org/10.1200/JCO.2017.76.6212
|
[42]
|
Shitara, K., Ajani, J.A., Moehler, M., Garrido, M., et al. (2022) Nivolumab plus Chemotherapy or Ipilimumab in Gastro-Oesophageal Cancer. Nature, 603, 942-948. https://doi.org/10.1038/s41586-022-04508-4
|
[43]
|
Doki, Y., Ajani, J.A., Kato, K., Xu, J.M., et al. (2022) Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medi-cine, 386, 449-462.
https://doi.org/10.1056/NEJMoa2111380
|